BioSpace News Archive

Koning Health, the leading innovator in breast CT technology, and Gentle Scan Health, LP, a venture firm dedicated to supporting better breast imaging options, are thrilled to announce their strategic partnership.

ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic therapy to treat a range of solid tumors, announced the appointment of Eyal Morag, M.D., as Chief Medical Officer.

Foundation for Sarcoidosis Research announces $100,000 in funding for support of research aimed at improving diagnosis, management, and treatment of cardiac sarcoidosis.

Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced that its CEO, Andrew Toy, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 12:00 p.m. Eastern Time.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and CS.

CymaBay Therapeutics, Inc. announced the grant of inducement awards to four employees on December 15, 2023 in connection with the employees’ commencement of employment at CymaBay.

ADMA Biologics, Inc. announced the Company has executed a definitive credit agreement with Ares Management credit funds for $135 million in total senior secured credit facilities, including a $72.5 million asset-backed revolving credit facility and a $62.5 million term loan.

Kronos Bio, Inc. (Nasdaq: KRON) today announced an update on its pipeline. After a review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the Company has decided not to proceed to phase 2.

bluebird bio, Inc. announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock.

Jasper Therapeutics, Inc. announced that, on December 14, 2023, three new employees were awarded grants of options to purchase an aggregate of 240,000 shares of voting common stock.